Registry for patients with relapsed and refractory hepatoblastoma
Relapsed and Refractory Hepatoblastoma: A Prospective Registry and Hepatic Tumors Research Consortium Initiative
This study is trying to gather information from patients with relapsed or hard-to-treat hepatoblastoma to better understand the disease and improve treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Sex | All |
| Sponsor | Children's Hospital Medical Center, Cincinnati Academic / other |
| Locations | 1 site (Cincinnati, Ohio) |
| Trial ID | NCT05556642 on ClinicalTrials.gov |
What this trial studies
This project aims to collect and analyze clinical, demographic, and pathological data from patients diagnosed with relapsed or refractory hepatoblastoma (rrHBL). It will gather biological specimens and imaging data to enhance understanding of the disease's biology and treatment options. Patients will be identified through existing registries, clinician referrals, or direct family contact. The collected data will be securely stored and may facilitate future research on tumor modeling and drug testing.
Who should consider this trial
Good fit: Ideal candidates include patients of any age with a suspected or confirmed diagnosis of relapsed or refractory hepatoblastoma, as well as those under 6 years with Hepatocellular Malignant Neoplasm- Not Otherwise Specified.
Not a fit: Patients who are deceased or do not have a suspected or confirmed diagnosis of rrHBL will not benefit from this study.
Why it matters
Potential benefit: If successful, this initiative could lead to improved understanding and treatment options for patients with relapsed and refractory hepatoblastoma.
How similar studies have performed: While there is limited data on similar registries for rrHBL, the approach of collecting comprehensive clinical and biological data has shown promise in other cancer research initiatives.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients of any age with a suspected diagnosis (per treating oncologist/surgeon) or confirmed diagnosis of a rrHBL and all patients with Hepatocellular Malignant Neoplasm- Not Otherwise Specified (HCN-NOS) who are \<6 years of age at the time of initial diagnosis * To allow for tumor modelling to be performed with fresh tissue from these cases, patients with suspected rrHBL are eligible to enroll on study * Unless the patient is deceased, all patients and/or one parent or legal guardian must provide written informed consent as well as HIPAA/release of information consent Exclusion Criteria: * None
Where this trial is running
Cincinnati, Ohio
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States (Recruiting)
Study contacts
- Study coordinator: rrHBL Registry
- Email: rrHBLRegistry@cchmc.org
- Phone: 844-722-8774
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.